Disorders - Bulimia Nervosa
Pope, HG., Keck, PE., McElroy, SL., Hudson, JI.
42 women (aged 19-38 yrs) who met the Diagnostic and Statistical Manual of Mental Disorders-III--Revised (DSM-III--R) criteria for bulimia nervosa completed a placebo-controlled, double-blind study with the antidepressant trazodone (TZ). Findings indicate that TZ was significantly superior to placebo, both in reducing the frequency of binge eating and vomiting and in several of the Ss' subjective ratings of improvement. Excluding 3 Ss who were probably not compliant with their medication, 7 of 17 Ss taking TZ experienced at least a 50% reduction in binge eating episodes and rated themselves as "very much" or "moderately" improved. However, only 2 of these Ss experienced a complete remission of binge eating. TZ produced few bothersome side effects. (PsycINFO Database Record (c) 2008 APA, all rights reserved).
Journal of Clinical Psychopharmacology, 9(4) : 254-259
- Year: 1989
- Problem: Bulimia Nervosa
- Type: Randomised controlled trials
-
Stage: Disorder established (diagnosed disorder)
-
Treatment and intervention: Biological Interventions (any)
, Other antidepressants
Hudson, J. I., Pope Jr, H. G., Keck Jr, P. E., McElroy, S. L.
In a 6-week, placebo-controlled, double-blind study of trazodone in 42 women with bulimia nervosa, trazodone was well tolerated and proved significantly superior to placebo in reducing the frequency of episodes of binge eating and vomiting. Nine- to 19-month follow-up of 36 study subjects revealed that 26 (72%) continued improved, with 18 (36%) in remission. Most remained on trazodone or another antidepressant at follow-up.
Clinical Neuropharmacology., 12(SUPPL. 1) : S38-S46
- Year: 1989
- Problem: Bulimia Nervosa
- Type: Randomised controlled trials
-
Stage: Disorder established (diagnosed disorder)
-
Treatment and intervention: Biological Interventions (any)
, Tricyclic antidepressants
Mitchell, JE., Christenson, G., Jennings, J., Huber, M., et-al.,
16 normal-weight bulimic women (mean age 23.7 yrs) were treated with 50 mg naltrexone (NA) and placebo in a crossover design. Ss completed the Hamilton Rating Scale for Depression and a self-monitoring instrument at weekly clinic visits. Findings show that NA was not associated with a clinically significant reduction in bingeing or vomiting. (PsycINFO Database Record (c) 2008 APA, all rights reserved).
Journal of Clinical Psychopharmacology, 9(2) : 94-97
- Year: 1989
- Problem: Bulimia Nervosa
- Type: Randomised controlled trials
-
Stage: Disorder established (diagnosed disorder)
-
Treatment and intervention: Biological Interventions (any)
, Other biological interventions
Berry, Diana M., Abramowitz, Stephen I.
27 female college students were randomly assigned to 1 of 4 conditions: (1) educative/support group plus experimental stimulus, (2) educative/support group plus neutral stimulus, (3) attention/placebo plus experimental stimulus, and (4) attention/placebo plus neutral stimulus. The educative/support group had significant ameliorative effects on bingeing and symptoms of emotional distress, regardless of whether or not it was paired with subliminal psychodynamic activation. Decreases in several psychological traits associated with eating disorders were found among all Ss irrespective of treatment conditions. Subliminal psychodynamic activation appeared to exert an independent treatment effect on restrained eating and certain symptoms of emotional distress. Clinical and theoretical implications are discussed and related to current proposed etiologies of bulimia. (PsycINFO Database Record (c) 2008 APA, all rights reserved).
International Journal of Eating Disorders, 8(1) : 75-85
- Year: 1989
- Problem: Bulimia Nervosa
- Type: Randomised controlled trials
-
Stage: Disorder established (diagnosed disorder)
-
Treatment and intervention: Psychological Interventions (any)
, Psychodynamic/Psychoanalysis, Psychoeducation
Blouin, AG., Blouin, JH., Perez, EL., Bushnik, T, et-al.,
Administered desipramine and fenfluramine to bulimic adults in a 15-wk study of double-blind, placebo-controlled, crossover design. The 22 Ss met Diagnostic and Statistical Manual of Mental Disorders (DSM-III) criteria for bulimia and were of normal weight. An eating disorder inventory, the Profile of Mood States, bulimia symptom checklists, and the SCL-90 were administered at Weeks 0, 2, 4, 6, 9, 11, 13, and 15. Results indicate that both drugs had beneficial effects on bingeing and vomiting frequency, although a greater proportion of Ss were identified who responded to fenfluramine. Both drugs were also effective in reducing the psychological symptoms of bulimia, such as the urge to binge and feelings of depression. (PsycINFO Database Record (c) 2008 APA, all rights reserved).
Journal of Clinical Psychopharmacology, 8(4) : 261-269
- Year: 1988
- Problem: Bulimia Nervosa
- Type: Randomised controlled trials
-
Stage: Disorder established (diagnosed disorder)
-
Treatment and intervention: Biological Interventions (any)
, Tricyclic antidepressants, Appetite moderators
Russell, G. F. M., Checkley, S. A., Feldman, J., Eisler, I.
A double-blind, placebo-controlled trial of d-fenfluramine in bulimia nervosa was undertaken in order to assess its efficacy in controlling bulimic behavior and relieving more general symptoms. A high proportion of the patients evaluated were reluctant to enter the drug trial in spite of the offer of additional supportive psychotherapy and counselling on dietary control. Moreover, 17 out of the 42 enrolled patients withdrew halfway through the 12 week trial. Were it not for this high rate of defaulting, there might be clearer support for the efficacy of d-fenfluramine in reducing the frequency of overeating and self-induced vomiting in these bulimic patients. An unexpected finding was that among the noncompleters, those on d-fenfluramine had experienced relief of their bulimic symptoms. The persistence of depressive symptoms and features of the eating disorder probably contributed to the noncompleters leaving the trial. Reassuring findings were the absence of weight loss and serious unwanted effects from d-fenfluramine. By itself, d-fenfluramine did not benefit some of the patients with severe bulimia nervosa, but it may yet prove a useful adjunct to psychological treatments.
Clinical Neuropharmacology., 11(SUPPL. 1) : S146-S159
- Year: 1988
- Problem: Bulimia Nervosa
- Type: Randomised controlled trials
-
Stage: Disorder established (diagnosed disorder)
-
Treatment and intervention: Biological Interventions (any)
, Appetite moderators
Russell, Gerald F., Szmukler, George I., Dare, Christopher, Eisler, I.
Evaluated the use of family therapy (FT) in treating 57 anorexic and 23 bulimic outpatients (mean age 21.8 yrs). Ss were randomly assigned to FT or individual supportive therapy (IST) and a follow-up was conducted at 1 yr. Results indicate that FT was more effective than IST in nonchronic patients who began treatment before age 19 yrs. In older patients, IST led to more weight gain than FT, but this improvement fell short of recovery in most Ss. Duration of hospital stay, use of antidepressant medication, differences in FT frequency, and dropout rates are examined as sources of bias. The effects of FT on members of the family other than the patient are discussed. It is concluded that anorexia's clear-cut symptoms and the availability of reliable outcome measures make it useful for evaluating treatments. (PsycINFO Database Record (c) 2008 APA, all rights reserved).
Archives of General Psychiatry, 44(12) : 1047-1056
- Year: 1987
- Problem: Anorexia Nervosa, Bulimia Nervosa
- Type: Randomised controlled trials
-
Stage: Disorder established (diagnosed disorder)
-
Treatment and intervention: Psychological Interventions (any)
, Family therapy, Supportive therapy
Fairburn, Christopher G., Kirk, Joan, O'Connor, Marianne, Cooper, Peter J.
Compared 2 standardized psychological treatments for bulimia nervosa--a cognitive behavioral approach and a short-term focal psychotherapy. 24 female patients (mean age 22.9 yrs) with bulimia nervosa were randomly allocated to the 2 treatments. Assessments took place at the beginning and end of treatment and at 4-, 8-, and 12-mo follow-up. Ss in both groups made substantial improvements that were well maintained over the 12-mo treatment-free follow-up period. The cognitive behavioral approach was superior to short-term focal psychotherapy in terms of its effect on the Ss' overall clinical state, their general psychopathology and social adjustment, and their assessment of their outcome. (54 ref) (PsycINFO Database Record (c) 2008 APA, all rights reserved).
Behaviour Research & Therapy, 24(6) : 629-643
- Year: 1986
- Problem: Bulimia Nervosa
- Type: Randomised controlled trials
-
Stage: Disorder established (diagnosed disorder)
-
Treatment and intervention: Psychological Interventions (any)
, Cognitive & behavioural therapies (CBT)
, Other Psychological Interventions
Hughes, Patrick L., Wells, Lloyd A., Cunningham, Carol J., Ilstrup, Duane M.
Conducted a double-blind, placebo-controlled, partial-crossover trial to study the effect of desipramine hydrochloride (target dose 200 mg/day) treatment, using 22 18-40 yr old bulimic patients without major depressive disorder. Results show that desipramine demonstrated both a significant benefit in comparison with placebo and a clinically significant benefit in comparison with baseline status. Improvement was equal in Ss both in and out of the blind study protocol, and it persisted at 1-mo follow-up. (15 ref) (PsycINFO Database Record (c) 2008 APA, all rights reserved).
Archives of General Psychiatry, 43(2) : 182-186
- Year: 1986
- Problem: Bulimia Nervosa
- Type: Randomised controlled trials
-
Stage: Disorder established (diagnosed disorder)
-
Treatment and intervention: Biological Interventions (any)
, Selective serotonin reuptake inhibitors (SSRIs)
Robinson, P. H., Checkley, S. A., Russell, G. F.
Fifteen patients with bulimia nervosa received fenfluramine (60 mg po) or placebo under double-blind, randomly ordered conditions. Two hours later food was presented. Significantly less food was eaten after fenfluramine and the quantity eaten was inversely correlated with serum fenfluramine levels. Significantly fewer patients reported bulimic symptoms during the test after fenfluramine, but no significant effect was demonstrated after leaving the ward. Fenfluramine caused drowsiness but did not reduce hunger ratings. Similarly, eating failed to reduce hunger ratings normally in the patients. These findings suggest that in patients with bulimia nervosa, hunger is reported abnormally and eating is suppressed by fenfluramine. Bulimic symptoms were probably reduced by fenfluramine, which may prove to be a useful treatment for bulimia nervosa.
British Journal of Psychiatry, 146 : 169-76
- Year: 1985
- Problem: Bulimia Nervosa
- Type: Randomised controlled trials
-
Stage: Disorder established (diagnosed disorder)
-
Treatment and intervention: Biological Interventions (any)
, Appetite moderators
Mitchell, J. E., Groat, R.
Bulimia is an eating disorder characterized by a pattern of episodic binge-eating. Patients with this eating disorder frequently demonstrate depressive symptoms when seen for evaluation. A familial association between bulimia and affective disorders has also been suggested. The authors report a placebo-controlled, double-blind trial of amitriptyline hydrochloride in a series of 32 female outpatients who satisfied DSM-III criteria for bulimia. The results of this study indicated that amitriptyline hydrochloride at a dosage of 150 mg at bedtime had significant antidepressant activity in this group of patients. Patients in both the placebo and active drug group also received a minimal behavioral treatment program in addition to drug therapy. Both groups demonstrated considerable improvement in eating behavior. The magnitude of this improvement was dramatic and not anticipated. The drug was well tolerated and was not associated with weight gain or increased carbohydrate craving.
Journal of Clinical Psychopharmacology, 4(4) : 186-93
- Year: 1984
- Problem: Bulimia Nervosa
- Type: Randomised controlled trials
-
Stage: Disorder established (diagnosed disorder)
-
Treatment and intervention: Biological Interventions (any)
, Tricyclic antidepressants
Sabine, E. J., Yonace, A., Farrington, A. J., Barratt, K. H., Wakeling, A.
British Journal of Clinical Pharmacology, 15 (Suppl 2) : S195-S202
- Year: 1983
- Problem: Bulimia Nervosa
- Type: Randomised controlled trials
-
Stage: Disorder established (diagnosed disorder)
-
Treatment and intervention: Biological Interventions (any)
, Tricyclic antidepressants